http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021197852-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a4783407e23a20dbe43d383a5d0fcb5
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D271-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D271-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
filingDate 2021-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8719f1359aed6ee3805fbd6bc4a2a4bd
publicationDate 2021-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2021197852-A1
titleOfInvention Crystalline form of ozanimod hydrochloride
abstract The presented invention relates to crystalline form, Form A of Ozanimod hydrochloride, processes for preparation thereof and pharmaceutical compositions comprising the Ozanimod hydrochloride Form A.
priorityDate 2020-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018050091-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3508481-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3470400-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019042219-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017215617-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018215807-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011060392-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3677575-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25110515
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID52938427
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228326010
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227627035

Total number of triples: 26.